Stock Report

All about this stock under one free report Last Updated: 13-May-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Sigilon Therapeutics Inc (SGTX)

Stock Card factsheet share-fund-plan-icon

$22.47

$0.00 (0.00%)

As on 18-Aug-2023 09:30EDT

Market cap

info icon

$56 Mln

Revenue (TTM)

info icon

$18 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

0.3

Div. Yield

info icon

0 %

Sigilon Therapeutics Inc (SGTX) Share Price

Compare

High:loading Low:loading Return: loading

Max:loading Min:loading Median:loading

Max:loading Min:loading Median:loading

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 22.47 High: 22.47

52 Week Range

Low: -- High: --

Liquidityliquidity

Low Moderate High

Fundamentals

  • Net Profit (TTM)Net Profit (TTM) information

    $-16 Mln

  • ROEROE information

    -0.8 %

  • ROCEROCE information

    -- %

  • Industry P/EIndustry P/E information

    --

  • EV/EBITDAEV/EBITDA information

    0.7

  • Debt to EquityDebt to Equity information

    0

  • Book ValueBook Value information

    $--

  • EPSEPS information

    $-3.7

  • Face valueFace value information

    --

  • Shares outstandingShares outstanding information

    2,501,900

5 Years Aggregate

CFO

$-203.27 Mln

EBITDA

$-233.49 Mln

Net Profit

$-243.89 Mln

Performance

Company
YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Sigilon Therapeutics Inc (SGTX)
393.8 4.8 253.5 152.0 -- -- --
BSE Sensex*
-11.9 -3.8 -10.8 -9.5 6.3 8.9 11.2
S&P Small-Cap 600#
-5.8 -5.3 -13.7 -6.3 5.3 3.0 5.5
As on 18-Aug-2023  |  *As on 13-May-2026  |  #As on 26-Oct-2023
Company
2022
2021
Sigilon Therapeutics Inc (SGTX)
-87.3 -94.3
S&P Small-Cap 600
-17.4 25.3
BSE Sensex
4.4 22.0

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details
Quarterly Annual

*All values are in ($ Mln)

Annual

*All values are in ($ Mln)

Annual

*All values are in ($ Mln)

Key Ratios

View Details

5Y Avg -- 3Y Avg -- TTM --

P/E Ratio

--

--Min --Median --Max

P/B Ratio

--

--Min --Median --Max

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

Shareholding Pattern

View Details
These are advertorial stories which keeps Value Research free for all. Click here to mark your interest for an ad-free experience in a paid plan

About Sigilon Therapeutics Inc (SGTX)

Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and...  SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.  Read more

  • Pres, CEO & Director

    Dr. Rogerio Vivaldi Coelho M.B.A., M.D., MBA

  • Pres, CEO & Director

    Dr. Rogerio Vivaldi Coelho M.B.A., M.D., MBA

  • Headquarters

    Cambridge, MA

  • Website

    https://www.sigilon.com

Value Research Ratings

Our rating system has guided millions of investors in the past 20 years.

Top Rated Stocks

All stocks with 5-star Value Research Ratings

Top Rated Stocks Icon

High Quality Small Caps

Small-cap stocks rated high on quality score

High Quality Small Caps Icon

High Growth Large Caps

Large-cap stocks with a high growth score

High Growth Large Caps Icon

Value Meets Momentum

Top momentum stocks with a high valuation score

Value Meets Momentum Icon

Top Rated Banks

Banks that rate high on Value Research Stock Ratings

Top Rated Banks Icon
Explore Screeners
Edit peer-selector-edit

FAQs for Sigilon Therapeutics Inc (SGTX)

The share price of Sigilon Therapeutics Inc (SGTX) is $22.47 (NASDAQ) as of 18-Aug-2023 09:30 EDT. Sigilon Therapeutics Inc (SGTX) has given a return of 151.96% in the last 1 years.

Since, TTM earnings of Sigilon Therapeutics Inc (SGTX) is negative, P/E ratio is not available.
The P/B ratio of Sigilon Therapeutics Inc (SGTX) is 0.25 times as on 18-Aug-2023, a 94 discount to its peers’ median range of 4.49 times.


PE & PB ratio at the end of financial year.


Year P/E Ratio P/B Ratio
2022
-0.26
0.29
2021
-1.14
1.16
2020
-11.58
4.35
2019
--
--
2018
--
--

The 52-week high and low of Sigilon Therapeutics Inc (SGTX) are Rs -- and Rs -- as of 13-May-2026.

Sigilon Therapeutics Inc (SGTX) has a market capitalisation of $ 56 Mln as on 18-Aug-2023. As per SEBI classification, it is a Small Cap company.

Before investing in Sigilon Therapeutics Inc (SGTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.
Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.